Introduction {#s0005}
============

The presence of clinically significant portal hypertension has important prognostic implications.[@bb0005], [@bb0010] Spleen stiffness (SS) is now widely used as novel non-invasive parameter to screen for portal hypertension[@bb0015], [@bb0020] outscoring liver stiffness (LS) or platelet count in predicting complications of portal hypertension such as the presence of esophageal varices and the risk of variceal bleeding.[@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045], [@bb0050] In fact, combining both LS and SS is currently considered the best predictor of portal hypertension.[@bb0015], [@bb0055] Although transient elastography (TE) was originally designed to measure LS, it can also be used to assess SS.[@bb0015], [@bb0045] Limitations are small or normal sized spleens, and obesity. Since SS is typically higher than LS, the upper detection limit of the FibroScan® device at 75 kPa is more rapidly reached, which has resulted in the development of a technically modified FibroScan prototype with an extended measuring range.[@bb0060]

However, less attention has been paid to SS as a function of disease etiology. For instance, LS clearly depends on disease etiology which has resulted in different F4 cirrhosis cut-off values, *e.g.* for patients with viral hepatitis or cholestatic liver disease.[@bb0065], [@bb0070] While this is still an ongoing debate, it has been well settled that inflammation is a key modifier of LS for common liver disease such as viral hepatitis or alcohol-related liver disease (ALD).[@bb0065], [@bb0075], [@bb0080], [@bb0085] Moreover, resolution of inflammation has been demonstrated to result in lowered LS both upon viral clearance in patients with hepatitis C virus (HCV)[@bb0090] and alcohol detoxification in patients with ALD.[@bb0080], [@bb0095] In patients undergoing antiviral treatment, it is not completely clear to what extent the decreased LS is due to resolution of inflammation or fibrosis. In contrast, data on alcohol withdrawal show a clearer picture. Here, withdrawal from alcohol for less than a week can result in complete resolution of inflammation and consequent normalization of aminotransferases and LS. Consequently, the LS resolution in such a short time period is solely due to resolving inflammation. Interestingly, in a recent large multicenter trial with 2,068 patients with biopsy-proven HCV and ALD, it was demonstrated that the LS cut-off values clearly depended on inflammation as measured by aspartate aminotransferase (AST) levels.[@bb0065] Moreover, identical AST levels caused a much higher increase of LS and related cut-off values in patients with ALD than in those with HCV. These findings are also in agreement with histological established sides of inflammation. Thus, ALD has been characterized mainly as a lobular disease, while chronic hepatitis C is predominantly seen as a portal disease.[@bb0100], [@bb0105], [@bb0110], [@bb0115] Consequently, it has been suggested that the localization of inflammation and fibrosis (portal *vs.* lobular) could be an additional critical factor that determines LS.[@bb0120]

Therefore, we aimed to analyze and compare SS, spleen length (SL) and LS in patients with portal (HCV) and lobular (ALD) chronic liver disease in a multicenter prospective cohort. Second, we studied the changes in these parameters in response to treatment. Finally, based on a retrospective cohort with long-term surveillance, we analyzed the association of LS and SL with clinical end points such hepatic decompensation and death.

Patients and methods {#s0010}
====================

Patient cohorts and clinical data {#s0015}
---------------------------------

The study design is shown in [Fig. 1](#f0005){ref-type="fig"} encompassing a total of 860 patients with both ALD and HCV. The local ethics committee approved the study protocol and informed consent was obtained from all patients. The overall study consists of 2 major Caucasian cohorts. Group A represents prospectively recruited patients from Heidelberg/Germany (n = 289), Odense/Denmark (n = 96) and Gluj Napoca/Romania (n = 26) with and without treatment while group B consists of a retrospective cohort from Germany (n = 352) and Great Britain (n = 97) with long-term follow-up data, LS parameters, SL and information on liver-related events and survival.Fig. 1**Study design.**ALD, alcohol-related liver disease; DAA, direct-acting antiviral; HCV, hepatitis C virus; LS, liver stiffness; SL, spleen length; SS, spleen stiffness.Fig. 1

For group A (411 patients), we prospectively recruited 191 patients with ALD and 220 patients with HCV. All patients were analyzed cross-sectionally for LS, SS, SL, ultrasonographic findings and routine lab parameters. In addition, we studied LS and SS in response to treatment interventions such as alcohol withdrawal or antiviral therapy in 65 patients with ALD and all 220 with HCV. Patients with ALD were 18 to 75 years of age and reported a prior or ongoing use of alcohol exceeding the maximum recommended limit of 3 units per day for men and 2 units per day for women (1 unit = 12 grams of alcohol), with a period of excessive drinking of at least 1 year. Patients with ALD represented a wide range of disease stages, from no fibrosis (F0) to F4 end-stage cirrhosis without clinically defined alcoholic hepatitis (see also [Table 1](#t0005){ref-type="table"}). In patients with ALD, all other potential causes of chronic liver disease such as viral hepatitis, autoimmune disease, iron overload disease and Wilson's disease were ruled out according to standard guideline recommendations. All patients with HCV had quantitative PCR before treatment and had no other etiology for chronic liver disease except HCV. Patients with HCV and concomitant alcohol use were also excluded. Data from patients with HCV were further verified for non-reported alcohol consumption by analyzing AST/ALT ratio, gamma glutamyltransferase and mean corpuscular volume levels.[@bb0125]Table 1Patient characteristics and cross-sectional comparison of ALD and HCV cohorts.Table 1ParameterALD (n = 191)HCV (n = 220)*p* value[⁎](#tf0005){ref-type="table-fn"}Age (years)55.3 ± 10.150.7 ± 11.10.0016Gender (male)73%63%0.14BMI (kg/m^2^)26.2 ± 4.324.1 ± 4.00.0016DM (present)22%27%0.3120Bilirubin total (mg/dl)1.1 (0.5-1.7)0.7 (0.5-0.9)≪0.0001AST (U/L)46 (32-75)45 (29-68)≪0.0001ALT (U/L)35 (22-51)46 (29-68)≪0.05Hemoglobin (g/dl)10.7 ± 3.213.4 ± 2.0≪0.0001Leucocytes (10^3^/μl)7.3 ± 2.97.5 ± 6.80.5436Platelets (10^3^/μl)194 ± 85172 ± 800.095INR1.2 ± 0.391.1 ± 0.120.048Creatinine (mg/dl)0.60 ± 0.370.87 ± 0.650.0068APRI2.1 ± 1.21.8 ± 1.10.0188Liver size (cm)16.1 ± 2.914.3 ± 1.6≪0.0001Spleen size (cm)11.9 ± 2.915.6 ± 3.6≪0.0001Liver stiffness (kPa)31.0 ± 25.214.9 ± 10.3≪0.001CAP (dB/m)285 ± 67298 ± 490.2692Spleen stiffness (kPa)32.6 ± 21.742.0 ± 16.6≪0.0001SL/LS ratio0.86 ± 0.791.46 ± 0.83≪0.0001SS/LS ratio1.72 ± 1.313.8 ± 3.08≪0.0001Fibrosis stages (non-invasive)0.0028 F013.6%15.0% F1-222.2%30.0% F38.5%16.8% F455.7%38.2%[^1][^2]

The effect of alcohol withdrawal was studied in 65 patients for a mean time interval of 5.3 consecutive days following complete normalization of aminotransferase levels. These patients were heavy drinkers that primarily presented for alcohol detoxification to the hospital. Patients with HCV received the combination of sofosbuvir/daclatasvir +/- ribavirin for 3 months. Second LS and SS measurements were obtained after 10 days of treatment in 81 patients and after 4 weeks in 139 patients. At both time points, aminotransferase levels had normalized. Viral clearance was confirmed by quantitative PCR in all patients before the second measurement. In some analysis (see result section), patients with ALD and HCV were matched for LS, age, gender and body mass index (BMI) to further analyze and compare SS, SL, portal pressure, serum bilirubin, international normalized ratio (INR) and platelet count between both groups.

For group B (449 patients), we retrospectively accrued data on 182 patients with ALD and 267 with HCV, including the base line characteristics, sonographic data (liver size, SL and LS) and laboratory features. The patients were followed up for 7 years or until the date of death, with the incidence of various forms of decompensation recorded: jaundice (serum bilirubin level \>2 mg/dl associated with yellowish discoloration of skin or sclera and radiological exclusion of biliary obstruction), variceal bleeding (diagnosed by upper gastrointestinal endoscopy), ascites (clinical diagnosis confirmed by ultrasonographic finding) or hepatic encephalopathy (clinical diagnosis). The mode of first decompensation was noted, in addition to the date of death or last visit. All data were retrieved from either admission or follow-up records.

Liver and spleen stiffness measurements {#s0020}
---------------------------------------

LS and SS were measured by TE (FibroScan, Echosens, Paris, France). TE was performed by physicians with at least 12 months of experience in abdominal ultrasound. TE of the liver was performed on the right lobe of the liver in the intercostal position using the M and XL probe. LS measurements were first started with the M probe with a measuring failure in 3.2% of all patients. In these patients, the XL probe was used according to the established protocols, yielding valid measurements without any exception.[@bb0125] TE of the spleen was also done using the M (89.5%) or XL (10.5%) probe after determining the spleen size using ultrasonography while the patient was lying in the supine position with the left arm maximally abducted. The tip of the transducer was placed in the left intercostal space, mostly in the posterior axillary line, then 10 successful measurements were obtained.[@bb0015], [@bb0045] Valid SS measurements were obtained in 82% of patients. The mean success rate of LS measurements was 96% while it was 79% for SS measurements. Liver fibrosis stages were determined using recently established algorithms including the consideration of aminotransferase levels.[@bb0065], [@bb0125] In addition, liver size and ascites formation were assessed by abdominal ultrasound. Patients with mechanic cholestasis, liver congestion and nodular masses were excluded from the study. Patients with failed LS and SS measurements were also excluded from the analysis.

Statistical analysis {#s0025}
--------------------

The statistical analysis was performed using SPSS Statistics version 25.0 (IBM, USA). For comparison of groups, we used the independent samples *t* test, chi-square test (for comparison of observed frequencies) and Mann-Whitney *U* test where appropriate. We reported the mean and the standard deviation in all parameters except in serum bilirubin, AST and alanine aminotransferase (ALT, not normally distributed) where median and interquartile range are given. For analysis of measurements before and after treatment, we used the paired-samples *t* test. Results were considered statistically significant when *p* values were lower than 0.05. All reported *p* values were uncorrected and 2-tailed. Matching for LS (65 ALD *vs.* 130 HCV) was performed, choosing 2 patients with HCV for 1 patient with ALD for the following LS ranges: 6--12 kPa, 12--20 kPa, 20--40 kPa and 40--55 kPa. Higher LS values were omitted because no LS-measurements above 55 kPa were observed in the HCV cohort. Patients could be selected so that age, BMI and gender were also not significantly different between the ALD and HCV group.

Results {#s0030}
=======

Patients with HCV exhibit higher SS and SL compared to those with ALD {#s0035}
---------------------------------------------------------------------

Since there are no established quality criteria for SS, we used all SS measurements with 10 successful measurements and we applied the established criteria used for LS.[@bb0130] Accordingly, valid or reliable measurements of SS could be obtained in 85% of patients.[@bb0130] As shown in [Table 1](#t0005){ref-type="table"}, in the overall cross-sectional cohort, SL (15.0 *vs.* 11.9 cm) and SS (42.0 *vs.* 32.6 kPa, *p≪*0.001) were significantly higher in HCV patients despite a significantly lower LS (31.0 *vs.* 14.9 kPa) compared to ALD. Although patients with HCV and ALD differed in the cross-sectional cohort with regard to age (51 *vs.* 55 years, *p* = 0.01) and BMI (24.1 *vs.* 26.2, *p* = 0.001), no statistically significant differences were observed for gender and diabetes mellitus. We also noted that serum bilirubin levels and INR were higher in ALD (1.1 *vs.* 0.7 mg/dl, *p≪*0.0001 and 1.2 *vs.* 1.12, *p≪*0.001, respectively), while mean platelet count was lower in patients with HCV (202 *vs.* 172 \[10^3^/μl\], *p≪*0.05). To rule out cohort-specific differences, we further matched both HCV and ALD cohorts for LS, age and gender and performed further analysis (see [Fig. 2](#f0010){ref-type="fig"}A and B). Although no significant differences were observed with regard to LS (19.0 *vs.* 19.8 kPa, *p* = 0.63), [Fig. 2](#f0010){ref-type="fig"}A demonstrates that spleens were significantly larger and SS was higher in HCV (11.8 *vs.* 14.9 cm and 27.8 *vs.* 47.8 kPa, *p≪*0.00001, respectively). [Fig. 2](#f0010){ref-type="fig"}B shows additional important differences between HCV and ALD in the matched cohorts. Thus, patients with HCV exhibited significantly lower platelet counts (195 *vs.* 139 \[10^3^/μl\], *p≪*0.0001), while bilirubin (1.6 *vs.* 0.9 mg/dl, *p≪*0.0001) and INR were significantly elevated in ALD (1.4 *vs.* 1.0, *p≪*0.0001).Fig. 2**Differences between patients with ALD and HCV matched for fibrosis stage, age, gender and BMI.** (A) Spleen stiffness and spleen length are significantly higher in HCV. (B) Comparison of other important parameters in the matched cohorts. (unpaired test, \*\*\**p ≪*0.001).ALD, alcohol-related liver disease; AST, aspartate aminotransferase; BMI, body mass index; HCV, hepatitis C virus; INR, international normalized ratio; LS, liver stiffness; SS, spleen stiffness.Fig. 2

Similar data were obtained when matching the patients for SS. Likewise, ALD patients had significantly higher LS (34.3 *vs.* 11.2 kPa, *p≪*0.001, see also Table S3). Notably, due to these differences, the AST to platelet ratio index (APRI) score, commonly used as a fibrosis score, was higher in patients with ALD without fibrosis than in all other stages with fibrosis (see Table S1). In contrast, in HCV, the APRI score continuously increased with fibrosis stage. Finally, in a subgroup of ALD (n = 17) and HCV (n = 25) matched for LS, we were able to measure portal vein pressure during transjugular portosystemic shunt implantation. Despite similar LS levels (52.4 \[ALD\] *vs.* 48.6 kPa \[HCV\]), patients with HCV had a significantly higher portal vein pressure (33.0 *vs.* 25.1 mmHg, respectively, *p≪*0.0001) (data not shown). In conclusion, we demonstrate a significantly elevated SS and SL in patients with HCV compared to ALD, even after matching for LS.

Identical SS to spleen association in HCV and ALD {#s0040}
-------------------------------------------------

To get further insights into the observed differences in SS and SL between ALD and HCV, we plotted organ size as a function of organ stiffness for both diseases (see [Fig. 3](#f0015){ref-type="fig"}A and B). Interestingly, as shown in [Fig. 3](#f0015){ref-type="fig"}A, no differences were observed between ALD and HCV with regard to SS and SL. In other words, patients with similar SS showed identical SL irrespective of whether they had HCV or ALD. This indicates that SS and SL seem to be the sole result of portal hypertension while additional *e.g.* extrahepatic disease-specific confounders are negligible. SL correlated highly with SS, following a linear function (see [Fig. 3](#f0015){ref-type="fig"}A) with a coefficient of determination of 0.91 and no significant differences between both diseases. In contrast, liver size and LS differed substantially between HCV and ALD. Thus, in HCV, liver size continuously decreased with increasing LS while livers from patients with ALD were much larger. In summary, these data confirm that the differences between ALD and HCV are predominantly due to differences in liver size and stiffness, while SS and SL do not differ.Fig. 3**Relation of organ stiffness to size for liver and spleen.** (A) Both in HCV[@bb0200] and ALD (black), SL is linearly correlated with SS (R^2^=0.91). (B) Liver size plotted against LS for both HCV and ALD. The liver size gradually decreases with the progression of LS in HCV (see linear regression line). In contrast, large livers are observed with increasing LS in ALD. Regression graphical analysis and coefficient of determination (R^2^).ALD, alcohol-related liver disease; HCV, hepatitis C virus; LS, liver stiffness; SL, spleen length; SS, spleen stiffness.Fig. 3

SS/LS ratio is significantly higher in HCV through all fibrosis stages {#s0045}
----------------------------------------------------------------------

Our observations of significantly elevated SS to LS, or SL to LS ratio in HCV compared to ALD suggested to us that the underlying etiology had an important role in these measures. Thus, the portal localization of inflammation and fibrosis in HCV could explain the higher SS compared to the higher LS in patients with ALD and pronounced lobular disease. Since the site of inflammation is strongly dependent on fibrosis stage and will eventually encompass the whole liver in both diseases, we further postulated that fibrosis stage might have an important role on the SS/LS ratio. Consequently, we next studied in more detail the SS to LS ratio in patients with various fibrosis stages for both diseases using a recently established non-invasive algorithm.[@bb0065] Indeed, the SS/LS ratio decreased with increasing fibrosis stage both in ALD and HCV (see [Fig. 4](#f0020){ref-type="fig"}A). Notably, SS/LS ratio was highest in early HCV with still normal LS exceeding a ratio of 5. In contrast, the highest SS/LS ratios in ALD reached levels of 2.6, but also continuously decreased with advancing liver disease. Notably, the SS/LS ratio overlapped between high fibrosis with HCV and low fibrosis with ALD. Similar data were obtained for SL ([Fig. 4](#f0020){ref-type="fig"}B). When plotting SS and SL directly against LS, both SS and SL were higher in HCV for the total LS range (see Fig. S1A and B). SS/LS ratio was also significantly higher in patients with HCV than ALD (3.3 *vs.* 1.3 for SS ≥40 kPa, *p≪*0.001, see Table S4) when stratifying patients according to the SS cut-off values for clinically significant portal hypertension.[@bb0135] Taken together, both SS and SL to LS ratio are higher in HCV, most likely due to the specific histological site of inflammation/fibrosis.Fig. 4**Spleen stiffness or spleen length to liver stiffness ratios for HCV and ALD as a function of fibrosis stage.** (A) SS to LS ratio and (B) SL to LS ratio according to fibrosis stage. Fibrosis stage was non-invasively assessed by TE using established AST-adapted cut-off values[@bb0065] (see methods section). SS, SL to LS-ratios are always significantly higher in HCV in each fibrosis stage. Given are mean and standard deviations (unpaired test, \*\**p≪*0.01, \*\*\**p≪*0.001).ALD, alcohol-related liver disease; AST, aspartate aminotransferase; HCV, hepatitis C virus; LS, liver stiffness; SL, spleen length; SS, spleen stiffness; TE, transient elastography.Fig. 4

SS/LS ratio is not changed after treatment intervention {#s0050}
-------------------------------------------------------

We now analyzed whether therapeutic interventions would have an impact on the SS/LS ratio in HCV and ALD. First, we studied the effect of alcohol withdrawal (mean interval 5.3 days) on laboratory markers, LS and SS. For comparison, we used a rather short follow-up protocol where the second measurements were obtained after 10 days and 4 weeks of standard direct-acting antiviral treatment protocol in patients with HCV (see patients and methods). All laboratory parameters including serum bilirubin, AST, ALT, INR and platelet count showed significant improvement after intervention in both diseases (see Table S2). Likewise, LS decreased significantly in both diseases (see [Fig. 5](#f0025){ref-type="fig"}). In contrast and although SS also decreased in both diseases after intervention, the decrease was only significant in patients with HCV (29.3 to 25.8 *vs.* 40.3 to 28.4 kPa, *p* = 0.18 and *p≪*0.0001, respectively). Consequently, the change in SS was more significant in patients with HCV than in those with ALD (-11.1 *vs.* -4.5 kPa, respectively, *p≪*0.0001, see [Fig. 5](#f0025){ref-type="fig"}). Finally, the SS to LS ratio did not change significantly during interventions in both diseases and there were no significant differences among HCV subgroups (not shown). In summary, although all stiffness parameters improved in both diseases after intervention, only patients with HCV showed a significant decrease of SS after treatment. Moreover, no significant changes in the SS/LS ratio were observed during intervention.Fig. 5**Change of liver stiffness and spleen stiffness during alcohol withdrawal (black) or HCV treatment**[@bb0200]. (A) Liver stiffness significantly declined after intervention in both ALD and HCV (Paired *t* test, \*\**p≪*0.01). (B) In contrast, spleen stiffness only significantly decreased after HCV treatment but not after alcohol detoxification (Paired *t* test \*\*\**p*≪0.001).ALD, alcohol-related liver disease; HCV, hepatitis C virus; LS, liver stiffness; SS, spleen stiffness.Fig. 5

SL and LS correlate with the mode of liver decompensation and death {#s0055}
-------------------------------------------------------------------

Finally, in a large retrospective cohort, we assessed whether the specific differences between patients with HCV and ALD would have an impact on the long-term outcome. Since SS was not available in this retrospective cohort, we focused on SL which showed a highly significant correlation with SS (see [Fig. 3](#f0015){ref-type="fig"}A). [Table 2](#t0010){ref-type="table"} shows long-term prognostic data for 182 patients with ALD and 267 with HCV who were clinically followed up for 7 years. Besides survival, final endpoints included signs of decompensation such as variceal bleeding, onset of jaundice, encephalopathy or ascites. Decompensation was noted in 118 patients with ALD and 153 with HCV. With 112 observations (73.2%, *p≪*0.0001 *vs.* ALD), variceal bleeding was the most frequent cause of first decompensation in the HCV group. In contrast, jaundice was the most frequent cause of first decompensation with 77 observations in the ALD cohort (65.2%, *p≪*0.0001). The incidence of variceal bleeding among dead patients was higher in HCV (95.3% *vs.* 16.2%, *p≪*0.0001), while the incidence of hepatocellular jaundice was much higher in the ALD group (93% *vs.* 28.1%, *p≪*0.0001). This follow-up cohort clearly demonstrates that patients with HCV are most likely to die from complications of portal hypertension, while patients with ALD are significantly more likely to experience liver failure with jaundice as a primary feature.Table 2Patient characteristics of the retrospective cohorts with long-term survival and complications.Table 2ALD (n = 182)HCV (n = 267)*p* value[⁎](#tf0010){ref-type="table-fn"}Age (years)57.2 ± 9.256.3 ± 12.00.396Gender (% male)77.5%74.1%0.193AST (U/L)39 (34-79)71 (36-105)≪0.001ALT (U/L)34 (21-53)45 (22-71)0.008Bilirubin (mg/dl)1.4 (0.8-2.1)0.7 (0.4-1.2)≪0.001Platelets (10^3^/μl)155 ± 8095 ± 70≪0.001Albumin (mg/dl)3.69 ± 0.433.81 ± 0.620.023INR1.09 ± 0.191.09 ± 0.260.989Creatinine (mg/dl)0.89 ± 0.780.78 ± 0.38≪0.001Liver size (cm)16.8 ± 3.213.5 ± 2.2≪0.001Spleen size (cm)12.5 ± 2.817.5 ± 4.2≪0.001Liver stiffness (kPa)32.7 ± 19.720.1 ± 11.3≪0.001SL/LS ratio0.62 ± 0.551.15 ± 0.67≪0.001Mortality43 (23.6%)64 (23.9%)Decompensation118 (64.8%)153 (57.5%)Mode of first decompensation Jaundice77 (65.3%)6 (3.9%)≪0.001 Variceal bleeding11 (9.3%)112 (73.2%)≪0.001 Ascites26 (22%)32 (20.9%)0.739 Encephalopathy4 (3.4%)3 (2.0%)0.329Incidence of decompensation modes within mortality cohort (over lifetime) Jaundice40 (93%)18 (28%)≪0.001 Variceal bleeding7 (16.2%)61 (95.3%)≪0.01 Ascites31 (72.1%)45 (70.3%)0.78 Encephalopathy29 (67.4%)46 (72%)0.34[^3][^4]

Discussion {#s0060}
==========

Herein, we demonstrate for the first time that both the SS to LS ratio as well as the SL to LS ratio are significantly higher in patients with HCV compared to ALD. In addition, they remain higher through all fibrosis stages and during therapeutic interventions. We further confirm in cohorts matched for LS that not only SS, but also the invasively measured portal pressure are higher in patients with HCV. Moreover, the association between SL and SS was comparable between ALD and HCV, while liver size was much larger in patients with ALD compared to HCV. Finally, in line with these observations, a long-term follow-up cohort clearly indicates that patients with HCV are more likely to have complications from portal hypertension, while patients with ALD are prone to develop complications of liver failure.

Our data suggest that non-invasive assessment of liver and spleen stiffness go far beyond the mere definition of fibrosis stage or prediction of portal hypertension. Rather, the SS/LS ratio seems to be determined by histological characteristics of the liver disease, namely the histological site of inflammation and fibrosis. Thus, portal inflammation with portal lymphoid aggregates are the histological hallmark of chronic hepatitis C and are established early on.[@bb0105], [@bb0140], [@bb0145], [@bb0150] In contrast, ALD is typically characterized by lobular inflammation in zone 3.[@bb0110], [@bb0115] Additional portal inflammation will only be observed in ALD during end-stage disease.[@bb0065], [@bb0155], [@bb0160] These established findings have been confirmed in previous histological studies on our ALD cohort.[@bb0080], [@bb0165] Moreover, a recent large multicenter trial on 2,068 patients with biopsy-proven HCV and ALD indicated important differences between both diseases with regard to LS and its response to inflammation.[@bb0065] In this study, inflammation translated into a much lower LS elevation in HCV compared to ALD. While these findings have direct implications for non-invasive fibrosis staging at the bedside, the aforementioned histological site of inflammation has been suggested to impact on LS in a recent hypothesis paper.[@bb0120] Accordingly, lobular inflammation/fibrosis in ALD should cause a more pronounced elevation of LS by intrahepatic congestion comparable to the extrahepatic liver congestion seen in heart failure.[@bb0170] In contrast, a portal disease such as HCV should have less impact on LS but a more pronounced effect on portal hypertension and SS.

This scenario seems to be confirmed by our findings. First, SL and SS, invasively measured portal pressure and complications of portal hypertensions were always higher or more frequent in patients with HCV. Second, liver size to LS clearly differs between HCV and ALD. While, during fibrosis progression, liver size continuously decreased in patients with HCV, it rather increased in patients with ALD up to a LS of 30 kPa and only thereafter started to decrease. These findings also underscore that the liver is primarily responsible for the differences in SS/LS ratio between HCV and ALD. Third and in contrast to the liver, no differences were observed between HCV and ALD with regard to the relation of length and stiffness of the spleen. In fact and surprisingly, SL performed almost as well as SS as a parameter in ALD and HCV despite other confounders of splenomegaly such as hemolysis or mTOR activation.[@bb0175], [@bb0180] This also has practical implications since SL can easily be assessed during commonly available abdominal ultrasound.

Our findings could also explain the disease-specific nature of fibrosis scores. For instance, the APRI score (ratio AST/AST upper limit divided by platelet count) that is widely used for fibrosis scoring in viral hepatitis performs poorly in ALD.[@bb0185] We recently showed that AST levels continuously increase in HCV with fibrosis stage, which is not the case for ALD.[@bb0065] This is also confirmed in the present study where the APRI score increased with fibrosis score in HCV but not at all in ALD (see also Table S1). Our present data provide a mechanistic rational for these observations. Thus, portal inflammation and fibrosis predominantly elevate portal pressure with subsequent elevation of spleen stiffness/size and reduction of platelets. In contrast, lobular ALD primarily increases LS most likely by intrahepatic congestion while portal pressure increases at later stages. Consequently, our data highlight the fact that fibrosis is not a uniform disease but strongly etiology dependent. In the future, this could lead to more specific fibrosis characterization and, potentially, a novel fibrosis classification.[@bb0120]

We were also surprised to learn that the long-term outcome and complications differ dramatically between HCV and ALD and are in line with our findings on LS and SS. Thus, variceal bleeding is the most common sign of decompensation and cause of death in patients with HCV, while jaundice is the most common sign of decompensation in patients with ALD. The possibility that the SS/LS ratio could help to optimize the diagnosis of liver diseases and predict liver-specific complications remains an attractive idea. Since there was no overlap of SS/LS ratio between ALD and HCV, the SS/LS ratio may be also useful to better characterize the role of additional alcohol consumption in patients with HCV. It remains to be studied whether other liver diseases such as Budd Chiari syndrome, other forms of viral hepatitis including hepatitis B virus, diseases such as Schistosomiasis will also fit into the herein presented concept of histological site and its impact on LS and SS. Single unpublished observations seem to underline the concept. For instance, in patients with liver congestion and heart failure, LS levels of 75 kPa are often observed in the absence of SS elevation reaching SS/LS ratios of 10 kPa/75 kPa = 0.13. In contrast, portal vein thromboses can cause drastically elevated SS up to 75 kPa in the presence of an almost normal LS corresponding to SS/LS ratios of ca. 20. Therefore, the SS/LS ratio could be a useful additional test for the diagnosis of liver disease.

Our study has some limitations which must be considered. We did not have liver biopsies in all patients. However, such studies have been performed and the association between LS and fibrosis score is well established for both HCV and ALD.[@bb0065], [@bb0190], [@bb0195] We also used the conventional FibroScan Touch with measurement failure of SS in 18% which could generate a study bias. It also remains unclear how different elastographic techniques such as acoustic radiation force impulse or magnetic resonance elastography will affect the ratio since they cannot be directly converted to FibroScan assess units and have a larger range of measurement. Echosens has recently introduced a device to allow measurements of higher SS values.[@bb0060] Finally, the lack of SS in the retrospective cohort makes it impossible to conclude whether SS is a stronger prognostic factor than SL.

In summary, we have demonstrated the disease-specific differences in SS to LS and SL to LS ratio between HCV and ALD. They underscore the role of the intrahepatic histological site of inflammation/fibrosis. We suggest that the SS/LS ratio could be used to confirm the disease etiology and predict disease-specific complications.
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[^1]: ALD, alcohol-related liver disease; ALT, alanine aminotransferase; APRI, AST to platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; DM, diabetes mellitus; HCV, hepatitis C virus; INR, international normalized ratio; LS, liver stiffness; SS, spleen stiffness.

[^2]: The statistical test used is unpaired *t* test.
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